A simple prediction model to estimate obstructive coronary artery disease

Shiqun Chen¹²³†, Yong Liu¹³†, Sheikh Mohammed Shariful Islam³†, Hua Yao¹, Yingling Zhou¹², Ji-yan Chen¹* and Qiang Li³

Abstract

Background: A simple noninvasive model to predict obstructive coronary artery disease (OCAD) may promote risk stratification and reduce the burden of coronary artery disease (CAD). This study aimed to develop pre-procedural, noninvasive prediction models that better estimate the probability of OCAD among patients with suspected CAD undergoing elective coronary angiography (CAG).

Methods: We included 1262 patients, who had reliable Framingham risk variable data, in a cohort without known CAD from a prospective registry of patients referred for elective CAG. We investigated pre-procedural OCAD (≥50% stenosis in at least one major coronary vessel based on CAG) predictors.

Results: A total of 945 (74.9%) participants had OCAD. The final modified Framingham scoring (MFS) model consisted of anemia, high-sensitivity C-reactive protein, left ventricular ejection fraction, and five Framingham factors (age, sex, total and high-density lipoprotein cholesterol, and hypertension). Bootstrap method (1000 times) revealed that the model demonstrated a good discriminative power (c statistic, 0.729 ± 0.0225; 95% CI, 0.69–0.77). MFS provided adequate goodness of fit (P = 0.43) and showed better performance than Framingham score (c statistic, 0.703 vs. 0.521; P < 0.001) in predicting OCAD, thereby identifying patients with high risks for OCAD (risk score ≥ 27) with ≥70% predictive value in 68.8% of subjects (range, 37.2–87.3% for low [≤17] and very high [≥41] risk scores).

Conclusion: Our data suggested that the simple MFS risk stratification tool, which is available in most primary-level clinics, showed good performance in estimating the probability of OCAD in relatively stable patients with suspected CAD; nevertheless, further validation is needed.

Keywords: Prediction model, Obstructive coronary artery disease, Framingham risk

Introduction

A report from the national cardiovascular data registry of the American College of Cardiology showed that only 41% of patients undergoing elective coronary angiography (CAG) are diagnosed as having obstructive coronary artery disease (OCAD); hence, a better risk stratification to increase pretest probability of coronary artery disease (CAD) appears warranted [1]. A recent meta-analysis (33 studies, 120,548 participants) suggested that OCAD in patients with acute coronary syndrome has a significantly higher cardiovascular risk at baseline and a higher likelihood of death or major cardiovascular events [2].

The classic risk stratification tool for CAD was the Framingham score system, which predicts the 10-year risk of coronary heart disease; however, the association of Framingham score with plaque burden is less robust [3, 4]. Although non-invasive diagnostic technology advancements, such as stress testing and computed tomography (CT) scanning adopted to increase the pretest probability of CAD in most tertiary hospitals, are available, high costs and unavailability limit their application in daily clinical practice. Ibrahim et al. recently established a new clinical and biomarker score with high accuracy for predicting the presence of anatomically significant CAD (≥70% stenosis), which included clinical
variables (male sex and previous percutaneous coronary intervention (PCI)) and four biomarkers (midkine, adiponectin, apolipoprotein C-I, and kidney injury molecule-1), among patients with known CAD (e.g., patients with previous acute myocardial infarctions (MI), who had PCI, or who underwent coronary artery bypass grafting (CABGJ)). However, whether this model could predict CAD in patients presenting at primary-level hospitals or clinics is unknown [5].

Therefore, this study aimed to establish a new simple prediction model, including traditional Framingham risk factors for OCAD, based on a continuously recruited at-risk cohort from an observational database investigating acute kidney injuries following elective CAG [6]. We hypothesized that the addition of new contemporary predictors to traditional Framingham risk factors could increase the accuracy of predicting anatomically significant CAD and, consequently, the novel model could be used in a broader population with suspected CAD.

Methods
Study population
The study population was derived from a prospective observational study PRECOMIN (NCT01400295) database between January 2010 and December 2013. The PRECOMIN study aimed at identifying the optimal contrast volume to prevent contrast-induced nephropathy among 3237 consecutive patients undergoing PCI/CAG, [6]. Patients who had previous PCI or previous MI, CABG, acute MI, or emergent PCI and those who lack total cholesterol (CHO) or high-density lipoprotein cholesterol (HDL-C) data were excluded (Additional file 1: Figure S1).

A total of 1262 patients without known CAD undergoing elective CAG were included in the analysis. The Institutional Ethics Research Committee approved the study, and all patients provided written informed consent.

Coronary angiography and data collection
CAG or PCI was performed according to the intervention cardiologist’s preference, which is guided by institutional policy and practice. Baseline data, angiographic characteristics, and medication data were prospectively defined and have been reported in a previous study [6]. During CAG, the highest percent stenosis value within each major coronary artery or their branches was recorded. High-sensitivity C reactive protein was tested with a Beckman Coulter Immage immunobiochemistry system (USA) using nephelometry (unit: mg/L). Left ventricular ejection fraction was calculated by using the biplane modified Simpson’s rule by Two-Dimensional Echocardiography.

Definition
The primary endpoint of our study was OCAD, which was defined as (≥50% stenosis by diameter in at least one major coronary vessel based on CAG) [2]. Anemia was defined according to the World Health Organization criteria, i.e., baseline hematocrit value < 39% for men and < 36% for women [7]. Hypertension was definite present if the participant was under treatment with antihypertensive medication or systolic ≥140 mmHg or diastolic ≥90 mmHg [3].

Statistical analysis
Continuous variables were compared with the t-test, and categorical variables were compared with the chi-square test or Fisher exact test, as appropriate. A logistic regression model was developed to predict OCAD in the PRECOMIN substudy. Significant predictors from the univariate analysis and non-significant variables with potential clinical relevance, including traditional Framingham risk factors, were evaluated as candidate factors (age, sex, smoking status, diabetes, CHO, high-density lipoprotein cholesterol [HDL-C], hypertension, baseline systolic blood pressure, and diastolic blood pressure, high-sensitivity C reactive protein [hs-CRP], left ventricular ejection fraction [LVEF], anemia, weight, serum creatinine, serum albumin, uric acid, HbA1c, Lp(a), blood urea nitrogen) to determine their association with OCAD in a variable model [3]. Collinearity and interaction between variables were also evaluated. Backward elimination approach was employed to create a reduced model by successively removing non-significant covariates until all the remaining predictors (age, sex, CHO and HDL-C, hypertension, smoke, anemia, hs-CRP and LVEF) are statistically significant (P < 0.1). Then, we manually investigated the contribution of the remaining predictors to find out the final predictors including age, sex, CHO and HDL-C, hypertension, anemia, hs-CRP, LVEF. We used regression coefficients from the model to generate point scores for predicting the probability of OCAD [8, 9]. The final prediction model was assessed using the area under the receiver operating characteristic (ROC) curve and concordance c-statistic for discriminative ability, and the Hosmer–Lemeshow goodness-of-fit statistic for calibration using fifths of the fitted risk values [10]. Moreover, the final model was tested by bootstrapping method (1000 times) to evaluate the stability of the c-statistics. We assumed that missing data occurred randomly, depending on the clinical variables and the CAG results. We performed multiple imputations using Markov chain Monte Carlo (MCMC) and fully conditional specification (FCS) [11–13]. Comparisons of baseline characteristics and OCAD incidence between patients with and those without missing values were performed [14, 15]. A P value < 0.05 was considered statistically significant in all tests. All analyses were performed using SAS version 9.3 (SAS Institute, Cary, NC).
Results
A total of 1262 patients with complete data were included in the final analysis (Additional file 1: Figure S1). The study subjects’ baseline characteristics, dichotomized as a function of the presence or absence of significant CAD, are detailed in Table 1. Numerous baseline characteristics differed between patients with (945, 74.9%) and those without OCAD.

Final modified Framingham prediction model
The final modified Framingham prediction model consisted of the following: anemia (odds ratio [OR], 1.556; P = 0.0053), hs-CRP (OR, 1.029; P = 0.0006), LVEF (OR, 0.979; P = 0.075), and five Framingham factors (age, sex, CHO and HDL-C, hypertension), and our model equation was “F(y) = -0.0468 + 0.0204(age) + 1.0961(gender) + 0.5444(hypertension) + 0.0055(CHO) -0.0257(HDL-C) -0.022(LVEF) + 0.5677(anemia) + 0.0254(hs-CRP)” (Table 2).

Modified Framingham scoring (MFS) system
In the entire cohort, the independent OCAD predictors were anemia, hs-CRP, and LVEF, while the Framingham risk factors were age, sex, CHO and HDL-C, and hypertension. Model fitting performed on the validation cohort showed that the MFS model performed better than the traditional Framingham model (Table 3).

Additionally, individual scores were subsequently calculated for patients in the validation cohort, and the results were expressed as a function of CAD presence. Consequently, a bimodal score distribution was found (Fig. 1), with higher OCAD prevalence in patients with higher scores and lower OCAD prevalence in those with lower scores. Moreover, a bimodal distribution of OCAD score was noted in the validation set (n = 683), with preponderance of patients with significant CAD with higher scores (positive: subjects with at least 1 coronary stenosis ≥50%; negative: subjects without coronary stenosis ≥50%).

Validation by bootstrap method and comparison of risk score
Bootstrap method (1000 times) revealed that the model demonstrated a good discriminative power (c-statistic, 0.729 ± 0.0225; 95% CI, 0.69–0.77).

In addition, the MFS provided adequate goodness of fit (P = 0.43). For the operating characteristics of the OCAD algorithm across various scores, the MFS model had a higher area under the ROC curve than the Framingham score (c-statistic, 0.703 vs. 0.521; P < 0.001); similarly, the modified Framingham risk factors model had a higher area under the ROC curve than the Framingham risk factors model (c-statistic, 0.719 vs. 0.693; P = 0.059) (Table 3; Fig. 2).

Moreover, the score was divided into four categories according to predicted risk (low risk score, ≤17; moderate risk score, 18–26; high risk score, 27–41; and very high risk score, ≥42), which allowed identifying patients with high risk for OCAD (risk score ≥27) with ≥70% predictive value in 68.8% of subjects (range, 37.2–87.3% for a low [≤17] and very high [≥41] risk score) (Fig. 3). The predicted risk of CIN in the validation set is presented in parallel to the observed OCAD prevalence in each risk group (Fig. 4).

Comparison between patients with missing data and those with complete data
Most of the baseline characteristics were similar between patients with missing data (n = 579) and those with complete data (n = 683). The missing data in the final model included gender, hypertension, smoking, CHO and HDL-C, and LVEF. Patients with missing data were younger and had lower hs-CRP level, systolic BP, and rate of anemia than patients with complete data. No significant difference in OCAD incidence (73.40 vs. 76.13%; P = 0.2648) was noted (Additional file 2: Table S1).

Comparison of patients with complete, MCMC, and FCS imputation data
We performed imputations of clinical variables and CAG results for 100 times using MCMC and FCS. Multivariate logistic regression and ROC curve were analyzed for the final modified Framingham model using complete and imputation data, and we found similar results, including ORs for predictor models and c-statistic by ROC analysis (0.719, 0.712, 0.711) (Additional file 3: Table S2 and Additional file 4: Table S3).

Discussion
In this study, Framingham risk score showed lower discrimination for OCAD prevalence in patients without known CAD undergoing elective CAG, whereas our new simple MFS model showed better performance in estimating the pretest probability of OCAD and identified more than two thirds of patients at high risk for OCAD.

Framingham risk score including traditional risk factors, which is the classic CAD risk-prediction model, showed less association with OCAD in the present study, which is consistent with a previous Canadian study that investigated the association of Framingham risk score with computed tomography angiography (CTA) measures of coronary atherosclerosis. Coronary atherosclerosis was present in 63.5% of the patients, which suggested a high prevalence similar to that in our study (74.9% of OCAD). Nevertheless, OCAD was diagnosed using CAG in our study, which may have more accuracy and significance for clinical decision than CTA [4].
Our simple modified Framingham risk score (FRS) might outperform FRS by ROC analysis, while we could not further calculate the net reclassification improvement to show how much improvement by using modified FRS to predict OCAD. Because FRS was to predict the 10-year risk of CAD, whose endpoint rate was lower than 15%,

| Variables                       | No (%) of patients with available data | Subjects without coronary stenosis ≥50% (n = 317) | Subjects with coronary stenosis ≥50% (n = 945) | P value |
|---------------------------------|---------------------------------------|-----------------------------------------------|-----------------------------------------------|---------|
| Demographic                     |                                       |                                               |                                               |         |
| Age                             | 1262(100)                             | 62.0 ± 10.4                                   | 64.2 ± 10.2                                   | < 0.001 |
| Gender, men                     | 1262(100)                             | 181(57.1%)                                    | 693(73.3%)                                    | < 0.001 |
| Signs and measurement           |                                       |                                               |                                               |         |
| Heart rate, beats/min           | 1261(99.9)                            | 73.4 ± 11.3                                   | 72.9 ± 11.9                                   | 0.49    |
| Systolic BP, mm Hg              | 1262(100)                             | 131.9 ± 17.9                                  | 132.7 ± 18.6                                  | 0.54    |
| Diastolic BP, mm Hg             | 1262(100)                             | 78.3 ± 12                                    | 77.5 ± 11.6                                   | 0.32    |
| Weight, kg                      | 1257(99.6)                            | 63.5 ± 9.5                                   | 65.2 ± 10.9                                   | 0.01    |
| Medical history                 |                                       |                                               |                                               |         |
| Smoking                         | 1262(100)                             | 80(26.2%)                                     | 347(36.7%)                                    |         |
| Hypertension                    | 1262(100)                             | 152(48.0%)                                    | 615(65.1%)                                    | < 0.001 |
| Congestive heart failure        | 1262(100)                             | 19(6.5%)                                      | 79(8.4%)                                      | 0.29    |
| Diabetes mellitus               | 1260(99.8)                            | 51(16.1%)                                     | 259(27.5%)                                    | < 0.001 |
| Hyperlipidemia                  | 1262(100)                             | 42(13.3%)                                     | 144(15.2%)                                    | 0.75    |
| Anemia                          | 1262(100)                             | 79(25.2%)                                     | 349(37.5%)                                    | < 0.001 |
| Medications                     |                                       |                                               |                                               |         |
| ACEI/ARB                        | 1262(100)                             | 240(75.7%)                                    | 864(89.5%)                                    | < 0.001 |
| Diuretics                       | 1261(99.9)                            | 36(11.4%)                                     | 91(9.6%)                                      | 0.38    |
| β-blocker                       | 1262(100)                             | 244(76.9%)                                    | 853(90.0%)                                    | < 0.001 |
| Statin                          | 1262(100)                             | 279(88.0%)                                    | 912(96.5%)                                    | < 0.001 |
| Calcium-channel blocker         | 1259(99.8)                            | 60(19.0%)                                     | 198(21.0%)                                    | 0.44    |
| Physical examination            |                                       |                                               |                                               |         |
| LVEF, %                         | 1013(80.3)                            | 64.6 ± 11                                     | 61.4 ± 11.9                                   | < 0.001 |
| Laboratory measures             |                                       |                                               |                                               |         |
| Total cholesterol, mg/dl        | 1262(100)                             | 168.2 ± 38.8                                  | 172.6 ± 64.6                                  | 0.15    |
| HDL-C, mg/dl                    | 1262(100)                             | 40 ± 10.8                                     | 36.8 ± 10.3                                   | < 0.001 |
| Triglyceride, μmol/l            | 1262(100)                             | 2.3 ± 11.8                                    | 1.6 ± 1.4                                     | 0.27    |
| LDL cholesterol, μmol/l         | 1262(100)                             | 2.5 ± 0.8                                     | 2.6 ± 0.9                                     | 0.19    |
| Lp (a), μmol/l                  | 1081(85.7)                            | 211.4 ± 231.1                                 | 287.2 ± 311.4                                 | < 0.001 |
| Blood urea nitrogen, mg/dl      | 1246(98.7)                            | 4.7 ± 1.6                                     | 5.2 ± 2.3                                     | < 0.001 |
| Serum Creatinine, μmol/l        | 1261(99.9)                            | 78.0 ± 29.6                                   | 89.7 ± 50.7                                   | < 0.001 |
| Hemoglobin, g/ml                | 1246(100)                             | 135.1 ± 15.1                                  | 133.3 ± 16.0                                  | 0.0929  |
| Serum albumin, g/l              | 1220(96.7)                            | 36.9 ± 4.1                                    | 36.1 ± 3.9                                    | 0.0035  |
| Urine pH                        | 1213(96.1)                            | 5.9 ± 0.7                                     | 6.0 ± 0.7                                     | 0.48    |
| HbA1c, %                        | 1043(82.6)                            | 6.3 ± 1.1                                     | 6.5 ± 1.2                                     | 0.006   |
| Hs-CRP, mmol/l                  | 849(67.3)                             | 3.8 ± 5.7                                     | 6.6 ± 13.0                                    | < 0.001 |
| Uric acid, mmol/l               | 994(78.8)                             | 364.6 ± 92.7                                  | 389.3 ± 102.5                                 | < 0.001 |
| B-type natriuretic peptide, pg/m| 1041(82.5)                            | 6094 ± 2061.0                                 | 7724.2 ± 2289.0                               | 0.29    |

LVEF = left ventricular ejection fraction; ACEI/ARB = angiotensin-converting enzyme inhibitor/angiotensin receptor blocker; HDL-C = high-density lipoprotein cholesterol; LDL-C = low-density lipoprotein-cholesterol; HbA1c = glycated hemoglobin; Hs-CRP = high-sensitivity C-reactive protein.
however, the modified FRS was to predict the OCAD with higher rate (more than 50%) for patients with suspected CAD, we could not find out ideal overlapping parts, ever after adopting all the cut-off value of endpoint rate [3].

This study established a novel, simple risk stratification method, which could be a useful tool in most primary-level hospitals or clinics and requires no large equipment or expensive examination in identifying patients with high risk for OCAD. Genders et al. established prediction models with a more accurate estimation of the pretest probability of OCAD in lower prevalence populations than that of the Duke clinical score, which is recommended by an American College of Cardiology guideline. However, to improve the model, coronary calcium score by CT scanning and classification of chest pain symptoms (i.e., typical, atypical, or non-specific) are necessary, which requires medical knowledge and experience or equipment and entails costs [16, 17].

Moreover, our results indicated that the use of MFS model suggested the yield of testing (i.e., the proportion of individuals referred for testing who have abnormal results) among patients with a high pretest probability [18]. More expensive or limited diagnostic tests in the risk stratification in a large community population can be addressed by the MFS model. In other word, the simple MFS model will improve the precision of risk stratification for more physicians, to increase invasive procedure among high risk patients, but to reduce invasive procedure among low risk patients.

For OCAD diagnosis, the modified Framingham score had a final area under the ROC curve of 0.703 in the validation set. Although the area under the ROC curves was less than that of previous studies, the performance of the MFS model was good [5, 18]. The small area under the ROC curve in our study could be attributed to the following: first, our study lacked more novel biomarkers, which were selected from nearly one hundred candidates variables [5]; second, the sample size was smaller than that of previous studies [16, 18]; third, we excluded subgroups with essential variables (e.g., PCI) or missed some significant variables (e.g., types of chest pain) [16].

One recent novel prediction score model in America for significant CAD showed better performance (c-statistic, 0.87 in the validation set); at the optimal cut-point, the score was both highly sensitive (77%) and specific (84%) for CAD diagnosis. The model included four biomarkers (midkine, adiponectin, apolipoprotein C-I, and kidney injury molecule-1). However, including these biomarkers (midkine, adiponectin, apolipoprotein C-I, and kidney injury molecule-1) in the routine examination in primary-level hospitals or clinics may not be suitable. In addition, the model was established in patients with or without known coronary disease and included previous PCI as a predictor. Our simple model includes traditional risk factors or routine examination without high cost. The development setting was also different, i.e., our simple model was based mostly on Chinese individuals; in the American model, Whites.

The modified Framingham score has three additional variables (i.e., hs-CRP, LVEF, and anemia), which could be associated with both anatomically OCAD and coronary events. A previous meta-analysis including 160,309 people without a history of vascular disease suggested that CRP concentration has continuous associations with the risk of

### Table 2

| Risk factors                  | Univariate logistic regression| Multivariate logistic regression |
|------------------------------|-------------------------------|---------------------------------|
|                              | OR 95% CI                     | OR 95% CI                       |
| Age, (per year)              | 1.11 (1.04–1.18)              | 1.02 (1.00–1.04)                |
| Gender (male vs. female)      | 2.07 (1.56–2.69)              | 2.99 (1.97–4.45)                |
| Hypertension (yes vs. no)     | 2.02 (1.56–2.62)              | 1.72 (1.17–2.55)                |
| Anemia (yes vs. no)           | 1.78 (1.33–2.37)              | 1.76 (1.14–2.72)                |
| LVEF (per %)                  | 0.97 (0.96–0.99)              | 0.98 (0.96–1.00)                |
| Hs-CRP (per mmol/l)           | 1.04 (1.01–1.07)              | 1.03 (1.00–1.05)                |
| TC (per 10 mg/dl)             | 1.02 (0.99–1.05)              | 1.06 (1.01–1.11)                |
| HDL-C (per mg/dl)             | 0.97 (0.96–0.99)              | 0.98 (0.96–0.99)                |

OR: odds ratio; CI: confidence interval; LVEF = left ventricular ejection fraction; Hs-CRP = high-sensitivity C-reactive protein; TC: total cholesterol; HDL-C = high-density lipoprotein cholesterol

*Univariate logistic regression analysis was performed in 1262 patients

*Multivariate logistic regression analysis was performed in 683 patients without missing data of the variables in the final model

### Table 3

| Model                          | AUC | AIC | HLG  | P value |
|--------------------------------|-----|-----|------|---------|
| Modified Framingham risk factors| 0.719 | 691 | 0.38 Reference |
| Framingham risk factors        | 0.693 | 705 | 0.35 0.059 |
| Modified Framingham score      | 0.703 | 689 | 0.43 Reference |
| Framingham score               | 0.521 | 753 | 0.03 < 0.001 |

AUC: area under the curve; AIC: Akaike information criterion; HLG: Hosmer and Lemeshow goodness-of-fit test
CAD, ischemic stroke, vascular mortality, and death from several cancers and lung diseases that are each of broadly similar size [19]. A Japanese observational study with a median follow-up period of 6.5 years showed that hs-CRP was associated with higher incidence of major adverse cardiac events or all-cause mortality in patients with established CAD and undergoing PCI [20]. The Atherosclerosis Risk in Communities (ARIC) study, which included 14,410 subjects (between 45 and 64 years) without CVD and had a follow-up duration of 6.1 years, showed that anemia is an independent risk factor for CVD outcomes [21]. Another recent cohort study of outpatients with stable CAD (21,829 with baseline hemoglobin levels) showed that anemia is a powerful predictor of cardiovascular and non-cardiovascular mortality [22]. Our study may be the first to identify anemia as a CAD predictor. A prospective study including 100 diagnostic coronary catheterization candidates found that the overall accuracy of akinesia/hypokinesia and LVEF < 55% in predicting abnormal CAG (≥50% stenosis) was poor [23]. Another study on 182 patients undergoing exercise Ti-201 gated single-photon emission computed tomography suggested that worsening of the LVEF during exercise has the potential to detect multivessel CAD among patients without multivessel patterns of reversible defects [24]. In our study, the LVEF measured by average echo could also be a CAD predictor. The predictive value of two new simple predictors (LVEF and anemia) needs further external validation in larger studies. Similarly, the new simple score model also requires further evaluation in relation to risk stratification. In addition, we would investigate the risk factors of dangerous culprit lesions with culprit plaque rupture (CPR) and thin-cap fibro-atheroma (TCFA), such as hypertension, advanced ages, diabetes mellitus or hyperlipidemia, which were evaluated by optical coherence tomography (OCT) or intravenous ultrasound (IVUS) in the futures [25].

Limitations

Our study has several limitations. First, our study adds significant information to the current literature on
pretest probability of OCAD for stable patients without known CAD; however, this is a single-center prospective observational study with a limited sample size. Second, angina types (e.g., classification of chest pain symptoms: typical, atypical, or non-specific) were not considered; thus, the accuracy of the OCAD risk model may have been affected. Thirdly, some bias in patient selection especially in CAG possibly existed; cardiologists tended to recruit patients with more baseline risk factors but with a stable condition for elective CAG. Thus, our findings may not be applicable to patients with low risk for OCAD or with emergent conditions. Fourthly, our study only focused on the anatomical result of angiography without kind of plaque evaluated with imaging (OCTs or IVUS), such as culprit plaque rupture (CPR) and thin-cap fibro-atheroma (TCFA), which could trigger acute coronary syndrome (ACS). Lastly, the high loss of follow-up rate possibly affected the quality of long-term prognosis and the predictive value of the modified Framingham score.

![Fig. 3 OCAD prevalence according to modified Framingham score](image1)

![Fig. 4 Scheme to define OCAD risk score](image2)
Conclusion
Our data suggested that the simple MFS risk stratification tool, which is available in most primary-level hospitals or clinics, showed good performance in estimating the pretest probability of OCAD and identified more than two thirds of relatively stable patients with suspected CAD at high risk for OCAD. Nevertheless, further external validation in larger studies is warranted.

Additional files

Additional file 1: Figure S1. Study flow. (PDF 54 kb)
Additional file 2: Table S1. Baseline Characteristics and incidence of obstructive coronary artery disease for patients with and without miss data of variables included in the final model. (DOCX 32 kb)
Additional file 3: Table S2. Multivariate logistic regression for the final modified Framingham model of complete and imputation data. (DOCX 19 kb)
Additional file 4: Table S3. Receiver operating characteristic curve for the final modified Framingham model of complete and imputation data. (DOCX 16 kb)

Abbreviations
CABG: Coronary artery bypass grafting; CAD: Coronary artery disease; CAG: Coronary angiography; CEI/ARB: Angiotensin-converting enzyme inhibitor/angiotensin receptor blocker; CHO: Total cholesterol; CT: Computed tomography; HbA1c: Glycated hemoglobin; HDL-C: High-density lipoprotein cholesterol; Hs-CRP: High-sensitivity C-reactive protein; LVEF: Left ventricular ejection fraction; MFS: Framingham scoring; MI: Myocardial infarctions; OCAD: Obstructive coronary artery disease; PCI: percutaneous coronary intervention; TC: Total cholesterol

Acknowledgements
Not applicable.

Conflicts of interest
The authors declare that they have no conflicts of interests.

Funding
Acquisition of data was supported by the Guangdong Provincial Cardiovascular Clinical Medicine Research Fund (grant number 2009X41 to Y.L. and N.T.) and Science and Technology Planning Project of Guangdong Province (PRECOMIN study by Y.L. in 2011 and study grant number 2008A030201002 to JYC). drafting the manuscript was supported by the Guangdong Cardiovascular Institute and Cardiovascular Research Foundation Project of the Chinese Medical Doctor Association (grant number SCRFCMDA201216 to JYC.). The funders had no role in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.

Availability of data and materials
The data that support the findings of this study are available from Jyian Chen, but restrictions apply to the availability of these data, which were used under license for the current study, and so are not publicly available. Data are however available from the authors upon reasonable request and with permission of Jyian Chen.

Authors’ contributions
SC, YL, JC, HY and QL: conception and design of the work; JC, HY, SC, YL, QL, and SL: acquisition, analysis, and interpretation of data; SC, HY, SC, YL, QL, and SL: drafting the manuscript and revising it critically for important intellectual content; SC, YL, SL, YZ, HY, JC, and QL: final approval of the version to be published. All authors agreed to be accountable for all aspects of the work and in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. All authors read and approved the final manuscript.

Authors’ information
Jiyan Chen takes responsibility for all aspects of the reliability and freedom from bias of the data presented and their discussed interpretation.

Ethics approval and consent to participate
The study was designed and implemented in accordance with the Guidelines for Good Clinical Practice and with the ethical principles laid down in the Declaration of Helsinki. All participants gave their written consent to participate in the study. The study was approved by Guangdong General Hospital institutional ethics research committee.

Consent for publication
Not applicable.

Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Department of Cardiology, Provincial Key Laboratory of Coronary Heart Disease, Guangdong Cardiovascular Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou 510100, China.
2Guangdong General Hospital Zuhai Hospital, Guangdong Academy of Medical Sciences, Zuhai 519000, China. 3The George Institute for Global Health, University of Sydney, Camperdown, NSW 2050, Australia.

Received: 29 May 2017 Accepted: 10 January 2018
Published online: 16 January 2018

References
1. Patel MR, Peterson ED, Dai D, Brennan JM, Redberg RF, Anderson HV, et al. Low diagnostic yield of elective coronary angiography. N Engl J Med. 2010; 362:886–95.
2. Pizzi C, Xhyheri B, Costa GM, Faustino M, Flacco ME, Gualano MR, Frassaggi G, Grigioni F, Manzoli L. Nonobstructive Versus Obstructive Coronary Artery Disease in Acute Coronary Syndrome: A Meta-Analysis. J Am Heart Assoc. 2016;5(12). http://jaha.ahajournals.org/content/5/12/e004185.
3. Wilson PW, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97(18):1837–47.
4. Pen A, Yam Y, Chen L, Dennie C, McPherson R, Chow BJ. Discordance between Framingham risk score and atherosclerotic plaque burden. Eur Heart J. 2013;34(14):1075–82.
5. Ibrahim NE, Januzzi JL Jr, Magaret CA, Gaggin HK, Rhyne RF, Gandhi PU, Kelly N, Simon-Mol, Motiwala SR, Belcher AM, van Kimmenade RR. A clinical and biomarker scoring system to predict the presence of obstructive coronary artery disease. J Am Coll Cardiol. 2015;66(9):1147–56.
6. Liu Y, Chen JY, Tan N, Zhou YL, Yu DQ, Chen ZJ, He YT, Liu YH, Luo JF, Huang WH, Li G, He PC, Yang JQ, Xie N, Liu XQ, Yang DH, Huang SJ, Piao-Ye, Li HL, Ran P, Duan CY, Chen PY. Safe limits of contrast vary with hydration volume for prevention of contrast-induced nephropathy after coronary angiography among patients with a relatively low risk of contrast-induced nephropathy. Circ Cardiovasc Interv. 2015;8(6) https://doi.org/10.1161/CIRCINTERVENTIONS.114.001859.
7. Nutritional anemias. report of a WHO Scientific Group. Geneva: World Health Organization; 1968.
8. Sullivan LM, Massaro JM, D’Agostino RB Sr. Presentation of multivariate data for clinical use: the Framingham study risk score functions. Stat Med. 2004; 23:1631–60. https://doi.org/10.1002/sim.1742.
9. Woodward M. Epidemiology: study design and data analysis. 3rd ed. London: Taylor & Francis; 2013. p. 605–78.
10. Steyerberg EW, Vickers AJ, Cook NR, Gerds T, Gonen M, Obuchowski N, et al. Assessing the performance of prediction models: a framework for traditional and novel measures. Epidemiology. 2010;21:38–48. https://doi.org/10.1097/ EDE.0b013e3181c30f8b.
11. van Buuren S, Boshuizen HC, Knoek DL. Multiple imputation of missing blood pressure covariates in survival analysis. Stat Med. 1999;18:681–94.
12. Karangwa DK. Using the Markov chain Monte Carlo method to make inferences on items of data contaminated by missing values. American
13. Liu Y, De A. Multiple imputation by fully conditional specification for dealing with missing data in a large epidemiologic study. Int J Stat Med Res. 2015;4(3):287–95.

14. Rubin DB, Schenker N. Multiple imputation in health-care databases: an overview and some applications. Stat Med. 1991;10:585–98.

15. Steyerberg EW, Borsboom GI, van Houwelingen HC, Eijkemans MJ, Habbema JD. Validation and updating of predictive logistic regression models: a study on sample size and shrinkage. Stat Med. 2004;23:2567–86.

16. Genders TS, Steyerberg EW, Hunink MG, Nieman K, Galama TW, Mollet NR, de Feyter PJ, Krestin GP, Alkadhi H, Leschka S, Desbiolles L, Meijer MF, Cramer MJ, Knaut J, Kjajander S, Bogaert J, Goetschalckx K, Cademartiri F, Maffei E, Martini C, Seinit S, Aldrovandi A, Wildermuth S, Stom B, Fornaro J, Feuchter G, De Zordo T, Auer T, Plank F, Friedrich G, Pugliese F, Petersen SE, Davies LC, Schoepf UJ, Rowe GW, van Mieghem CA, van Driessche L, Sinisyn V, Gopalakrishnan U, Bamborg FC, Cury RC, Battle J, Maurich-Horst P, Barydowska A, Merkely B, Becker D, Hadamidtsky M, Hausfeiler J, Dewey M, Zimmermann E, Laule M. Prediction model to estimate presence of coronary artery disease: retrospective pooled analysis of existing cohorts. BMJ. 2012;344:e3485. https://doi.org/10.1136/bmj.e3485.

17. Pryor DB, Harrell FE Jr, Lee KL, Califf RM, Rosati RA. Estimating the likelihood of significant coronary artery disease. Am J Med 1983;75:771–80.

18. Bittencourt MS, Hulten E, Polonsky TS, Hoffman U, Nasir K, Abbara S, Di CM, Blankstein R. European Society of Cardiology-Recommended Coronary Artery Disease Consortium Pretest Probability Scores More Accurately Predict Obstructive Coronary Disease and Cardiovascular Events than the diamond and Forrester score: the partners registry. Circulation. 2016;134(3):201–11.

19. The Emerging Risk Factors Collaboration. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet. 2010;375(9709):132–40. https://doi.org/10.1016/S0140-6736(09)61717-7.

20. Wada H, Doi T, Miyachi K, Shitara J, Endo H, Doi S, Naito R, Konishi H, Tsuboi S, Ogita M, Kasai T, Hassan A, Okazaki S, Isoda K, Shirama K, Suwa S, Daida H. Preprocedural high-sensitivity C-reactive protein predicts long-term outcome of percutaneous coronary intervention. Circ J. 2016;81(1):90–5.

21. Kalra PR, Greenlaw N, Ferrari R, Ford I, Tardif JC, Tendler M, Reid CM, Danchin N, Stepinska J, Steg PG, Tendera M, Danchin N, Stepinska J, Tardif JC, Tendera M, Reid CM, Danchin N, Stepinska J, Steg PG, Fox KM. Prospective observational Longitudinal Registry of patients with stable coronary artery disease (CLARIFY) Investigators. Hemoglobin and Change in Hemoglobin Status Predict Mortality, Cardiovascular Events, and Bleeding in Stable Coronary Artery Disease. Am J Med. 2017;130(6):720–30.

22. Lutfi MF. Diagnostic accuracy of resting left ventricular akinesia/hypokinesia in predicting abnormal coronary angiography. BMC Cardiovasc Disord. 2016;16:137. https://doi.org/10.1186/s12872-016-0312-5.

23. Yamagishi H, Shirai N, Yoshiyama M, Teragaki M, Akizawa T, Yoshikawa J, Ochi H. Incremental value of left ventricular ejection fraction for detection of multivessel coronary artery disease in exercise (201)Tl gated myocardial perfusion imaging. J Nucl Med. 2002;43(2):131–9.

24. Iannaccone M, Quadri G, Taha S, D’Ascenzo F, Montefusco A, Omede’ P, Jang IK, Niccoli G, Souteyrand G, Yundai C, Toutouzas K, Benedetto S, Barbero U, Anncone U, Lommi Y, Imoni Y, Biondi-Zoccola G, Tempilin C, Moretti C, Luscher TF, Gaeta F. Prevalence and predictors of culprit plaque rupture at OCT in patients with coronary artery disease: a meta-analysis. Eur Heart J Cardiovasc Imaging. 2016;17(10):1128–37.